O'Melveny Wins Injunction for Allergan in Botox Trade Secrets Case

   |0 Comments

Allergan execs probably grew some new frown lines when sales representatives for Botox, the company's best-selling wrinkle treatment, jumped ship for rival Merz Pharma GmbH just as Merz was rolling out a rival drug. Now its Merz that should be worried, though, thanks to a bench ruling that Allergan's lawyers at O'Melveny & Myers won on Tuesday.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202544779608

Thank you!

This article's comments will be reviewed.